Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Eptazocine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 5/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 8/20 | 0.46 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eptazocine SCHEMBL9487496 | 1.00 | HSD11B1 (0.50) | HSD11B1OPRM1OPRK1OPRD1SIGMAR1 | |
| Eptazocine SCHEMBL30901223 | 1.00 | HSD11B1 (0.50) | HSD11B1OPRM1OPRK1OPRD1SIGMAR1 | |
| Eptazocine SCHEMBL29388574 | 0.99 | HSD11B1 (0.51) | HSD11B1OPRM1OPRK1OPRD1SIGMAR1 | |
| Eptazocine SCHEMBL1650016 | 0.99 | HSD11B1 (0.51) | HSD11B1OPRM1OPRK1OPRD1SIGMAR1 | |
| Eptazocine SCHEMBL25862 | 0.99 | HSD11B1 (0.51) | HSD11B1OPRM1OPRK1OPRD1SIGMAR1 | |
| Bromide SCHEMBL11653724 | 0.82 | OPRM1 (0.50) | HSD11B1OPRM1OPRK1OPRD1SIGMAR1 | |
| SCHEMBL11651818 | 0.81 | SIGMAR1 (0.44) | OPRK1OPRD1SIGMAR1 | |
| SCHEMBL20394548 | 0.81 | HSD11B1 (0.52) | HSD11B1OPRM1OPRK1SIGMAR1MRGPRX2 | |
| SCHEMBL9488119 | 0.81 | HSD11B1 (0.52) | HSD11B1OPRM1OPRK1SIGMAR1MRGPRX2 | |
| SCHEMBL30945838 | 0.81 | SIGMAR1 (0.41) | HSD11B1OPRM1OPRK1OPRD1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 236 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118834169-A | Etazomib hydrobromide preparation method of octyl intermediate | 广州市联瑞制药有限公司 | 2024-10-25 | — | — | CN | claimed |
| CN-114236004-A | Method for measuring content of ethyl bromide in eptazocine hydrobromide intermediate | 深圳万乐药业有限公司 | 2022-03-25 | — | — | CN | claimed |
| CN-111961000-A | Eptazocine hydrobromide raw material medicine impurity and preparation method thereof | 深圳万乐药业有限公司 | 2020-11-20 | — | — | CN | claimed |
| CN-111925328-A | Eptazocine hydrobromide raw material medicine impurity b and preparation method thereof | 深圳万乐药业有限公司 | 2020-11-13 | — | — | CN | claimed |
| CN-110563605-A | Intermediate for preparing eptazocine hydrobromide and preparation method thereof | 上海医药工业研究院 | 2019-12-13 | — | — | CN | claimed |
| US-20060110333-A1 | Composition for nasal absorption | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2006-05-25 | — | — | US | claimed |
| US-20060014697-A1 | Pharmaceutical compositions for prevention of overdose or abuse | SHIRE LLC | 2006-01-19 | — | — | US | claimed |
| EP-1535615-A1 | COMPOSITION FOR NASAL ABSORPTION | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-01 | — | — | EP | claimed |
| US-20040058946-A1 | Abuse-resistant prodrugs of oxycodone and other pharmaceuticals | COLLEGIUM PHARMACEUTICAL, INC. | 2004-03-25 | — | — | US | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| JP-4217920-A | — | — | None | — | — | JP | disclosed |
| JP-1061447-A | — | — | None | — | — | JP | disclosed |
| JP-7010754-A | — | — | None | — | — | JP | disclosed |
| EP-2841109-B1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA AS (DK) | 2026-04-15 | — | — | EP | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| EP-0472969-A1 | External preparation comprising calcium silicate | Eisai Co., Ltd. (JP) | 1992-03-04 | — | — | EP | disclosed |
| EP-0452837-A2 | Adhesive device for transdermal administration of an active agent | NITTO DENKO CORPORATION (JP) | 1991-10-23 | — | — | EP | disclosed |
| WO-1991015241-A1 | PERCUTANEOUSLY ABSORBABLE COMPOSITION OF NARCOTIC AND NONNARCOTIC ANALGESICS | MORIMOTO YASUNORI (JP) | 1991-10-17 | — | — | WO | disclosed |
| EP-0384917-A1 | (+)-Or (+)-1-(2-N-substituted aminoethyl)-1-methyl-7-methoxy-1,2,3,4-tetrahydronaphthalene, and process for production thereof | Nihon Iyakuhin Kogyo Co., Ltd. (JP) | 1990-09-05 | — | — | EP | disclosed |
| JP-S6461447-A | (+-)-OR (+)-1-(2-N-SUBSTITUTED AMINOETHYL)-1-METHYL-7-METHOXY-1,2,3,4-TETRAHYDRONAPHTHALENE AND PRODUCTION THEREOF | NIHON IYAKUHIN KOGYO CO LTD | 1989-03-08 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058946-A1 | Abuse-resistant prodrugs of oxycodone and other pharmaceuticals | OPRK1, OPRM1, OPRL1 | SIGMAR1 6/4885HSD11B1 705/4885OPRM1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.